Kenya Receives First Shipment of Injectable HIV Vaccine Lenacapavir, a Game-Changer in Prevention
Kenya has received its first shipment of Lenacapavir, an injectable HIV pre-exposure prophylaxis (PrEP), marking a major step in the country’s fight against new HIV infections. The shipment, delivered on Tuesday, February 17, came through a partnership with the Global Fund and included 21,000 starter doses of the vaccine.
The doses, sourced from the United States, will form the first phase of a national rollout scheduled to begin in March 2026, targeting 15 high-burden counties. The initiative is part of Kenya’s commitment to innovative, people-centered approaches aimed at ending the HIV epidemic.
How Lenacapavir Works
Lenacapavir is a long-acting injectable PrEP that prevents HIV infection by targeting critical stages of the virus lifecycle, stopping it from establishing itself in the body. Unlike traditional daily pills, the injectable formulation is administered only twice a year, making prevention more convenient and improving compliance among patients.
Patrick Amoth, Health Director General, confirmed that an additional 12,000 continuation doses are expected in April to support patients already on the drug. Furthermore, another 25,000 doses from the U.S. Government will arrive later in 2026 to strengthen early implementation.
The government has set the estimated cost of the injectable vaccine at Ksh 7,800 per patient, a significant reduction from previous PrEP regimens, which cost approximately Ksh 4.2 million over a lifetime. The vaccine is FDA-approved (June 2025) and has also received the World Health Organization (WHO) approval, confirming its safety, quality, and effectiveness.
Rollout and Implementation
The first phase will be implemented by the National AIDS Control Programme (NASCOP) and will prioritize high-risk populations in the targeted counties. The introduction of Lenacapavir complements existing HIV prevention efforts, including mother-to-child transmission prevention, and supports Kenya’s goal of achieving Universal Health Coverage (UHC).
The injectable formulation is expected to increase access to HIV prevention, reduce the daily pill burden, and strengthen national efforts to curb new infections. By offering a twice-yearly alternative, Kenya aims to reach more at-risk populations, improve adherence, and make HIV prevention more convenient.
A Step Toward Ending HIV in Kenya
Kenya has been at the forefront of adopting innovative HIV prevention strategies, and the rollout of Lenacapavir represents a significant milestone. The government’s partnership with the Global Fund and support from the U.S. highlights international collaboration in fighting the epidemic.
Lenacapavir’s availability is expected to revolutionize HIV prevention, offering a long-acting, effective, and affordable solution for individuals at risk, while strengthening Kenya’s broader health system.